Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences

NCT ID: NCT05997732

Last Updated: 2026-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-31

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this interventional study is to examine differences in resting blood pressure control between healthy males and females. The main questions it aims to answer are:

1. Are there sex differences in the communication between the sympathetic nervous system (also known as the "fight or flight" response) and peripheral blood vessels (which influence systemic blood pressure)?
2. What is the role of specific vascular receptors that respond to sympathetic signals, and is it different between males and females?

Participants will complete one study visit of approximately 3 hours where they will:

* Have a blood sample taken to measure circulating sex hormone and sympathetic transmitters.
* Receive very small doses of medications commonly used to adjust blood pressure through an artery in their arm. The effects of these medications will be short-acting and localized to the forearm.
* Have their sympathetic nervous activity directly measured through two very small needles (similar to acupuncture needles) in the side of their leg.
* Have their blood pressure and heart rate recorded, and forearm blood flow measured using ultrasound.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Blood pressure is in part regulated by activity of your sympathetic nervous system (also known as your "fight or flight" response). Sympathetic nerve activity affects the size of your blood vessels, which in turn will affect your blood pressure. This communication between sympathetic impulses and the resulting change in vascular resistance is termed "sympathetic neurovascular transduction". In other words, transduction represents the reactivity of the blood vessels in response to individual sympathetic bursts of activity.

Males and females regulate their blood pressure in different ways; for example, females tend to have lower blood pressure and sympathetic nerve activity than males. Females also appear to have less constriction of their blood vessels in response to stress. This may be due to differences in the receptors which are activated by the sympathetic nervous system. These receptors are called α and β-adrenergic receptors and are located on vascular smooth muscle cells. They respond to sympathetic neurotransmitters such as norepinephrine in opposite directions: α-adrenoreceptors cause vasoconstriction (and an increase in vascular resistance), and β-adrenoreceptors cause vasodilation (and a decrease in vascular resistance) in part through the endothelium-dependent nitric oxide pathway.

Current evidence suggests that β-adrenergic receptors are more sensitive in females and contribute to paradoxical vasodilation when α-adrenergic receptors are stimulated by norepinephrine from sympathetic bursts. It has also been suggested that estrogen interacts with adrenergic receptors, contributing to this sex difference. This study will contribute to the understanding of sex differences in cardiovascular physiology and may have implications for clinical cardiovascular conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasoconstriction Vasodilation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Participants will complete three pharmacological conditions, and serve as their own controls.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Condition

Normal saline will be infused through the brachial artery catheter at the same calculated rate as propranolol + phentolamine in the α+β-blockade condition to control for volumetric effects.

Group Type EXPERIMENTAL

Phenylephrine Hydrochloride

Intervention Type DRUG

Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.

Isoproterenol Hydrochloride

Intervention Type DRUG

Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.

Norepinephrine Bitartrate

Intervention Type DRUG

Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.

β-Adrenergic Blockade

β-adrenoreceptors will be blocked locally in the forearm using propranolol. Normal saline will be co-infused at the calculated rate of phentolamine in the α+β-blockade condition to control for volumetric effects.

Group Type EXPERIMENTAL

Norepinephrine Bitartrate

Intervention Type DRUG

Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.

Propranolol Hydrochloride

Intervention Type DRUG

Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.

α+β-Adrenergic Blockade

α-adrenoreceptors will be blocked locally in the forearm using phentolamine. Propranolol will be co-infused to maintain β-blockade.

Group Type EXPERIMENTAL

Phentolamine Mesylate

Intervention Type DRUG

Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.

Phenylephrine Hydrochloride

Intervention Type DRUG

Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.

Isoproterenol Hydrochloride

Intervention Type DRUG

Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.

Propranolol Hydrochloride

Intervention Type DRUG

Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Phenylephrine Hydrochloride

Participants will receive three incremental doses via the brachial artery catheter to assess α1-adrenoreceptor mediated vasoconstriction.

Intervention Type DRUG

Isoproterenol Hydrochloride

Participants will receive four incremental doses via the brachial artery catheter to assess β-adrenoreceptor mediated vasodilation.

Intervention Type DRUG

Norepinephrine Bitartrate

Participants will receive three incremental doses via the brachial artery catheter to assess nonspecific adrenoreceptor activation.

Intervention Type DRUG

Propranolol Hydrochloride

Propranolol will be continuously infused through the brachial artery catheter to induce β-adrenergic blockade locally in the forearm.

Intervention Type DRUG

Phentolamine Mesylate

Phentolamine will be continuously infused through the brachial artery catheter to induce α-adrenergic blockade locally in the forearm.

Intervention Type DRUG

Phenylephrine Hydrochloride

Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the α-adrenergic blockade.

Intervention Type DRUG

Isoproterenol Hydrochloride

Participants will receive one dose via the brachial artery catheter to evaluate the effectiveness of the β-adrenergic blockade.

Intervention Type DRUG

Propranolol Hydrochloride

Propranolol will be continuously co-infused with phentolamine to maintain the β-adrenergic blockade.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between ages 18-40 years
* No diagnosed medical history of cardiovascular, respiratory, nervous system, or metabolic disease.
* Females must be pre-menopausal.
* Prior to study visit: abstained from caffeine, alcohol, strenuous exercise, and medication not taken regularly for at least 12 hours.

Exclusion Criteria

* Current diagnosis of cardiovascular, respiratory, nervous system, or metabolic disease that may impact blood pressure regulation. This will be assessed on a case-by-case basis by the study physician.
* Participants with bleeding or clotting disorders, or those currently taking blood thinners.
* Participants currently taking beta-agonist inhalers i.e. Ventolin (at least not in the last 24 hours).
* Females who are pregnant, confirmed by a pregnancy test.
* Females who have are less than 1 year postpartum or are breastfeeding.
* Females who are post-menopausal.
* Participants that are classified as obese (body mass index \> 30 kg ⋅ m2).
* Those with a known allergy to sulfites, or other components of the supplied solution of study drugs.
* Participants taking medications that are contraindicated with any of the study drugs, such as monoamine oxidase (MAO) inhibitors or tricyclic antidepressants.
* Participants who have not adhered to the pre-testing guidelines related to diet, alcohol or exercise will not be excluded, but will be rescheduled for a different day. This is to reduce experimental variability.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alberta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sean van Diepen, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Craig Steinback, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alberta

Edmonton, Alberta, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emily Vanden Berg, MSc

Role: CONTACT

(780)-492-5553

Nicholas Cheung, MSc

Role: CONTACT

(780)-492-5553

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Craig Steinback, PhD

Role: primary

(780)492-5553

References

Explore related publications, articles, or registry entries linked to this study.

Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach JH, Joyner MJ. Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension. 2009 Mar;53(3):571-6. doi: 10.1161/HYPERTENSIONAHA.108.126391. Epub 2009 Jan 26.

Reference Type BACKGROUND
PMID: 19171792 (View on PubMed)

Steinback CD, Fraser GM, Usselman CW, Reyes LM, Julian CG, Stickland MK, Chari RS, Khurana R, Davidge ST, Davenport MH. Blunted sympathetic neurovascular transduction during normotensive pregnancy. J Physiol. 2019 Jul;597(14):3687-3696. doi: 10.1113/JP277714. Epub 2019 Jun 13.

Reference Type BACKGROUND
PMID: 31106429 (View on PubMed)

Fairfax ST, Holwerda SW, Credeur DP, Zuidema MY, Medley JH, Dyke PC 2nd, Wray DW, Davis MJ, Fadel PJ. The role of alpha-adrenergic receptors in mediating beat-by-beat sympathetic vascular transduction in the forearm of resting man. J Physiol. 2013 Jul 15;591(14):3637-49. doi: 10.1113/jphysiol.2013.250894. Epub 2013 May 7.

Reference Type BACKGROUND
PMID: 23652594 (View on PubMed)

Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ. Post-junctional alpha-adrenoceptors and basal limb vascular tone in healthy men. J Physiol. 2002 May 1;540(Pt 3):1103-10. doi: 10.1113/jphysiol.2001.015297.

Reference Type BACKGROUND
PMID: 11986395 (View on PubMed)

Hissen SL, Taylor CE. Sex differences in vascular transduction of sympathetic nerve activity. Clin Auton Res. 2020 Oct;30(5):381-392. doi: 10.1007/s10286-020-00722-0. Epub 2020 Aug 31.

Reference Type BACKGROUND
PMID: 32865664 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00126600

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Variability in Adrenergic Response
NCT00838695 COMPLETED NA